![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Thursday, December 30, 2021 11:48:39 AM
https://www.prnewswire.com/news-releases/significantly-improved-safety-profile-and-metabolism-of-remdesivir-observed-due-to-encapsulation-in-nanoviricides-drug-candidate-enabling-potential-highly-effective-pan-coronavirus-antiviral-drug-301382343.html
That was two months ago.
"In brief, our platform technology based NV-387-encapsulated-RDV (NV-CoV-2-R) drug has a dual effect on coronaviruses. First, NV-CoV-2 itself as an antiviral regimen. Secondly, RDV is protected from plasma-mediated degradation in transit, rendering altogether the safest and an efficient regimen against COVID-19."
https://www.biorxiv.org/content/10.1101/2021.11.24.469813v1.full (note...preprint, not peer reviewed)
That was dated 11/26. (see Note)
"Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo."
https://www.nejm.org/doi/full/10.1056/NEJMoa2116846
That was last week.
Note:
One of the authors of the Preprint is listed as Jayant Tatake, who is referenced in the latest NNVC 10-K:
" On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and will issue an additional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date of the agreement. The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company."
Something changed at some point (when?) because the pre-print and JT's Linkedin listing describe him as "VP, R&D at AllExcel, Inc.,"
Ultimately, who pays him?
Al of the pre-print authors are employees of either Nanoviricides or Allexcel:
Author Information
Anil Diwan1, Ph.D., Ashok Chakraborty2*, Ph.D., Vijetha Chiniga2, MS, Vinod Arora2, Ph.D., Preetam Holkar2, MS., Yogesh Thakur2, MS., Jay Tatake2, Ph.D., Randall Barton1, Ph.D., Neelam Holkar2, MS. and Bethany Pond2, MS
1Nanoviricides, Inc., Shelton, CT, USA
2AllExcel, Inc., West Haven, CT, USA
So this is an interesting claim:
Conflict of Interests
Authors, Anil Diwan and Randall Barton are employed by the company Nanoviricides, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CNBC published an interesting release some time ago:
"CNBC also asked NanoViricides to clarify the relationship between TheraCour, AllExcel and NanoViricides, and any cash payments to AllExcel, but NanoViricides did not respond."
"“The patents have been assigned to AllExcel, Inc., the Company at which the groundbreaking work was performed. AllExcel, Inc. has contractually transferred this intellectual property to TheraCour Pharma, Inc.,” the company said in the 10-Q."
Diwan was a no-show for an agreed-to CNBC interview.
“The answers to all of your other questions are already publicly available in our press releases, regulatory filings, and on our website,” the statement from Diwan said.
https://www.cnbc.com/2020/07/14/biopharma-nanoviricides-sees-stock-soar-on-coronavirus-claims.html
As my dear old grandfather Litvak said (just before they swung the trap), he said "You can't cheat an honest man. Never give a sucker an even break or smarten up a chump."
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
FEATURED Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • Sep 4, 2024 9:02 AM
FEATURED Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • Sep 4, 2024 8:45 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM